|
Market Research Report
The Oncology Market Forecast to 2013
|
The Oncology Market Forecast to 2013 published by Cutting Edge Information in July, 2008. This report consists of 400 Pages and the price starts from US $ 9995.
Abstract
Give Your Team Access to the Most Comprehensive Oncology Forecast Ever
Created
Cutting Edge Information' s new report, "Oncology Market Forecast to 2013,"
explores the fiercely competitive oncology market in a way that no other
available forecast can match.
Our experienced analysts have reviewed thousands of historical and forecasted
data points to provide the most comprehensive oncology market outlook ever -
pulling together data from our own proprietary PharmaEdge databases, along
with hundreds of additional public and private databases worldwide.
Give your brand team all the oncology data it needs to make critical
product decisions!
Key Questions This Report Will Answer:
- Which drugs will make the most money in the next five years?
- Which drug classes are poised for exponential growth?
- Whose portfolio will allow them to jump out in front of the oncology
market?
Table of Contents
Chapter 1: Analysis of Cancer Drugs by Classes (130+ Drug Profiles)
- - BRAND INFORMATION
- Brand and generic name
- Drug class
- Delivery mechanism
- Line of treatment
- - SALES DATA
- Historical/current sales
- Forecasted sales
- - APPROVED INDICATIONS
- - CURRENT PRODUCT DEVELOPMENT PHASES
- - COMPETITIVE AND STRATEGIC POSITIONING
- - MARKET OPPORTUNITIES AND BRAND GROWTH
- - PATENT, GENERIC AND LITIGATION INFORMATION
Chapter 2: Oncology Indications
- - ANALYSIS OF MARKETS FOR DIFFERENT CANCER TYPES
- Current sales, major drugs and important companies
- Forecasted sales and assessment of future drugs and market players
- Pipeline development status
- Major market events, changes in treatments, patent expirations, etc.
Chapter 3: Top Companies' Oncology Portfolios
- - ANALYSIS OF MAJOR ONCOLOGY COMPANIES
- Current sales, major drugs and important companies
- Forecasted sales and assessment of future drugs and market players
- Pipeline development status
|
